Fixed dosing of HER antibodies
AssigneeGenentech, Inc.
InventorsDavid E. Allison, Rene Bruno, Jian-Feng Lu, Chee M. Ng
Life of this patent
Estimating the term…
Abstract
The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
Claims32
A method for treating HER2 expressing cancer comprising administering one or more fixed dose(s) of HER2 antibody to a human patient in an amount effective to treat the cancer, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of the HER2 antibody, wherein the HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.
A method of treating HER2 expressing cancer in a human patient comprising administering at least one fixed dose of pertuzumab to the patient, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of pertuzumab.
Dependencies are inferred from the claim text.